DRNCX Fees and Costs — BNY Mellon Alternative Diversifier Strategies Fund, Class C
Data updated: 2023-06-28
The net expense ratio is 2.81% (3.11% before fee waivers). This share class carries a deferred sales charge of up to 1.00%. Portfolio turnover was 14%.
DRNCX Fees and Expenses
Annual operating expenses and sales charges of DRNCX. Prospectus, as of October 31, 2022.
| Annual operating expenses | |
|---|---|
| Management fee | 0.25% |
| 12b-1 fee | 0.75% |
| Other expenses | 0.85% |
| Gross expense ratio | 3.11% |
| Fee waiver | −0.30% |
| Net expense ratio | 2.81% |
| Sales charges | |
|---|---|
| Max front load | 0.00% |
| Max deferred load | 1.00% |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | No |
DRNCX Costs Over Time
On $10,000 invested in DRNCX, assuming 5% a year before costs, total costs come to $1,695 over 5 years, cutting the return by 2.95% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Sales charges | $102 | $0 | $0 |
| Fund expenses (net expense ratio 2.81%) | $295 | $903 | $1,537 |
| Lost growth on money paid in costs | $0 | $45 | $158 |
| Total costs | $397 | $949 | $1,695 |
| Value after costs | $10,103 | $10,628 | $11,068 |
| Impact on return, per year | 3.97% | 2.95% | 2.95% |
DRNCX Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending October 31, 2022.
- Explicit cost rate (commissions ÷ average net assets): —
- Total broker commissions: —
- Bought from dealers (principal trades, not a cost): —
- Portfolio turnover (prospectus): 14%
- Securities lending: none during the year
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.